Will Quizartinib be included in medical insurance in 2024?

Quizartinib is an oral, highly effective type II inhibitor of FLT3, specifically used to treat FLT3-ITD mutated acute myeloid leukemia (AML). AML is a malignant clonal disease originating from hematopoietic stem cells in the bone marrow. It is characterized by abnormal proliferation of blast cells in the bone marrow, resulting in the suppression of normal hematopoietic function. FLT3-ITDMutation is one of the common molecular markers in AML and is associated with poor prognosis, high recurrence rate and short survival of patients.

Quizatinib selectively inhibits the activity of FLT3 tyrosine kinase and blocks the abnormal kinase activity caused by FLT3-ITD mutation, thereby inhibiting the proliferation of leukemia cells and inducing their apoptosis. The drug offers a new treatment option for patients with AML, especially those who have failed or relapsed with conventional chemotherapy.

The clinical application of quizartinib has shown significant efficacy. In the pivotal clinical trial, patients who received quizartinib in combination with standard induction and consolidation chemotherapy experienced a statistically significant improvement in overall survival and a significant reduction in the risk of death compared with placebo. These results fully demonstrate the effectiveness and potential of quizartinib in the treatment of AML.

However, the use of quizartinib is also associated with certain side effects and risks. Patients need to closely monitor QT interval, blood routine and other indicators during use, and may experience adverse reactions such as nausea, vomiting, diarrhea, and abnormal liver function. In addition, quizartinib may interact with other drugs, so you need to inform your doctor in detail about your medication history and allergy history before use.

Currently, Quizartinib has not yet been launched in China. Domestic patients cannot directly purchase this drug, so this drug is not included in domestic medical insurance projects. However, it is understood that the drug has been marketed overseas. The European original version is priced as high as about 80,000 yuan per box (17.7mg 28 tablets); while the Laotian imitation version is relatively cheap, priced at about 1,800 yuan per box (17.7mg 14 tablets).

In general, quizartinib is an anti-FLT3-ITD mutationAMLTargeted therapeutic drugs, their unique mechanisms and potential therapeutic effects bring new hope to patients. However, patient response and side effects need to be closely monitored during use to ensure the safety and effectiveness of the treatment.

xa0

Reference: https://www.drugs.com/mtm/quizartinib.html